mTOR inhibitors: all 1,276 studies that test it

Page 6 of 13. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.CompletedNCT00425308Phase 3Results posted
• Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and ChemotherapyCompletedNCT00419159Phase 2Results posted
• Efficacy and Safety of Sirolimus in LAMCompletedNCT00414648Phase 3Results posted
• Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4Results posted
• Everolimus and Octreotide in Patients With Advanced Carcinoid TumorCompletedNCT00412061Phase 3Results posted
• A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast CancerCompletedNCT00411788Phase 2Results posted
• Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1/2Results posted
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or SunitinibCompletedNCT00410124Phase 3Results posted
• RAD001 in Previously Treated Patients With Metastatic Pancreatic CancerCompletedNCT00409292Phase 2Results posted
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3Results posted
• Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung CancerTerminatedNCT00406276Phase 1/2Results posted
• Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00401778Phase 1Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT00397982Phase 2Results posted
• Sirolimus for Autoimmune Disease of Blood CellsCompletedNCT00392951Phase 1/2Results posted
• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney CancerCompletedNCT00392821Phase 1/2Results posted
• Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous TherapyTerminatedNCT00390364Phase 2Results posted
• Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host DiseaseCompletedNCT00388362Phase 2Results posted
• Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete RemissionCompletedNCT00382109Phase 3Results posted
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney CancerCompletedNCT00378703Phase 2Results posted
• Nordic Everolimus (Certican) Trial in Heart and Lung TransplantationCompletedNCT00377962Phase 4Results posted
• Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00376688Phase 2Results posted
• Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung CancerCompletedNCT00374140Phase 2Results posted
• SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using EverolimusCompletedNCT00371826Phase 4Results posted
• Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant RecipientsCompletedNCT00369382Phase 4Results posted
• A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant RecipientsCompletedNCT00369161Phase 4Results posted
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited DisordersTerminatedNCT00358657Phase 2Results posted
• Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell CarcinomaCompletedNCT00353301Phase 2Results posted
• TBI Dose De-escalation for Fanconi AnemiaCompletedNCT00352976Phase 2/3Results posted
• Belatacept to Prevent Organ Rejection in Kidney Transplant PatientsTerminatedNCT00346151Phase 2Results posted
• Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1/2Results posted
• Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.TerminatedNCT00332839Phase 4Results posted
• Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00331409Phase 2Results posted
• Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent GlioblastomaCompletedNCT00329719Phase 1/2Results posted
• De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular CarcinomaCompletedNCT00328770Phase 2/3Results posted
• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal CarcinomaCompletedNCT00323739Phase 2Results posted
• Comparison of Sirolimus and Azathioprine in Lung TransplantationCompletedNCT00321906Phase 4Results posted
• Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast CancerCompletedNCT00317720Phase 1/2Results posted
• Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate CancerCompletedNCT00311623Phase 1/2Results posted
• Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant PatientsTerminatedNCT00311311Phase 3Results posted
• Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular DegenerationCompletedNCT00304954Phase 2Results posted
• Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic RejectionCompletedNCT00300274Phase 3Results posted
• CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00290472Phase 2Results posted
• Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00286156Phase 1/2Results posted
• Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell TransplantationCompletedNCT00282282Phase 2Results posted
• Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By SurgeryCompletedNCT00281957Phase 2Results posted
• Individualized Drug Treatment for Treating Patients With Pancreatic CancerTerminatedNCT00276744Phase 2Results posted
• Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant RecipientsCompletedNCT00251004Phase 3Results posted
• Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation RecipientsCompletedNCT00240994Phase 2Results posted
• Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft FailureCompletedNCT00223678Phase 4Results posted
• Study Evaluating Sirolimus in Kidney Transplant RecipientsCompletedNCT00195273Phase 3Results posted
• Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African AmericansCompletedNCT00189202Phase 2/3Results posted
• ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant RecipientsCompletedNCT00170846Phase 4Results posted
• A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy ImmunosuppressionTerminatedNCT00166712Phase 4Results posted
• Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant PatientsCompletedNCT00154310Phase 4Results posted
• Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant PatientsCompletedNCT00154297Phase 4Results posted
• Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant PatientsCompletedNCT00154284Phase 3Results posted
• Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant RecipientsCompletedNCT00129961Phase 4Results posted
• RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMASCompletedNCT00126672Phase 2Results posted
• Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant RecipientsCompletedNCT00121810Phase 4Results posted
• Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)CompletedNCT00117598Phase 3Results posted
• RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaCompletedNCT00113360Phase 2Results posted
• CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00112840Phase 1/2Results posted
• CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109967Phase 2Results posted
• Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid TumorsCompletedNCT00106353Phase 1/2Results posted
• Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung CancerCompletedNCT00096486Phase 1/2Results posted
• Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
• RAD001 in Recurrent Endometrial Cancer PatientsCompletedNCT00087685Phase 2Results posted
• Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant RecipientsTerminatedNCT00086346Phase 3Results posted
• Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate CancerCompletedNCT00085566Phase 1/2Results posted
• Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior TreatmentCompletedNCT00079183Phase 2Results posted
• Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in AdultsCompletedNCT00078559Phase 1/2Results posted
• Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney TransplantationCompletedNCT00076570Phase 2Results posted
• Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial CancerCompletedNCT00072176Phase 2Results posted
• Study Evaluating Interferon And CCI-779 In Advanced Renal Cell CarcinomaCompletedNCT00065468Phase 3Results posted
• Study Evaluating Temsirolimus (CCI-779) In Breast NeoplasmsCompletedNCT00062751Phase 2Results posted
• Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital AnemiasActive, not recruitingNCT00061568Phase 1/2Results posted
• Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric SarcomasCompletedNCT00043979Phase 2Results posted
• Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant RecipientsCompletedNCT00038948Phase 3Results posted
• Islet Transplantation for Type 1 DiabetesCompletedNCT00014911Phase 2Results posted
• Sirolimus and Thymoglobulin to Prevent Kidney Transplant RejectionCompletedNCT00006178Phase 2Results posted
• Sirolimus Treatment in Pediatric Patients With Ataxia-TelangiectasiaCompletedNCT07820579Phase 2
• A Pilot Study on Reverse Aging (The REVERSE Study)Active, not recruitingNCT07354620Early Phase 1
• A Study of Exercise and Pharmacologic Intervention on Systemic InflammationActive, not recruitingNCT07058974Phase 1
• Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyActive, not recruitingNCT06957379Phase 2
• Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis NigricansCompletedNCT06940895Phase 2
• Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaSuspendedNCT06876142Phase 1/2
• Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal WomenActive, not recruitingNCT06789900Phase 2
• Sirolimus for Improving Social Abilities in People With PTEN Germline MutationsWithdrawnNCT06080165Phase 1/2
• Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission TomographyCompletedNCT06022068Phase 1/2
• Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)Active, not recruitingNCT05860881Phase 3
• Effect of Rapamycin in Ovarian AgingActive, not recruitingNCT05836025Phase 2
• Everolimus Aging StudyCompletedNCT05835999Phase 2
• Addition of Everolimus to Standard of Care in Carcinoma GallbladderStatus unknownNCT05833815Phase 2/3
• Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGGTerminatedNCT05773326Early Phase 1
• REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept StudyCompletedNCT05663944Phase 2
• A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)Status unknownNCT05625919Phase 1/2
• Adjunctive Everolimus Treatment of Refractory EpilepsyStatus unknownNCT05613166Phase 2
• Low-dose Interleukin-2 and Rapamycin on sjögren's SyndromeCompletedNCT05605665Phase 1/2
• Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.Status unknownNCT05532072Early Phase 1

← mTOR inhibitors overview